Overall, the results suggest that low-dose 2DG could potentially improve the anti-tumor T cell response not only by decreasing PD-L1 expression on tumor cells [38,39,40], but also by reducing PD-1 expression on T cells and boosting their secretion of IFN-γ. This evidence concerns the gene CD274 and neoplasm.